Drugs Affecting Blood and Blood Formation Practice Questions

Q: In which condition erythropoietin will be useful for treatment?

Anemia in chronic kidney disease. ***Anemia in chronic kidney disease*** - **Erythropoietin (EPO)** deficiency is the primary cause of anemia in chronic kidney disease (**CKD**), as the damaged kidneys cannot produce adequate amounts. - Recombinant human EPO (**rHuEPO**) is the standard treatment to stimulate **erythropoiesis** in the bone marrow, correcting the anemia and improving quality of life. ***Anemia in myelodysplastic syndrome*** - While erythropoiesis-stimulating agents (ESAs) like EPO are occasionally used in lower-risk myelodysplastic syndrome (**MDS**) patients, especially those who are transfusion-dependent, the response rates are variable and dependent on underlying cytogenetics and serum EPO levels. - The primary defect in MDS involves abnormal **hematopoietic stem cell function** (a primary bone marrow failure) rather than just EPO deficiency, making treatment difficult. ***Nutritional anemia*** - This category, including **iron deficiency anemia** and **megaloblastic anemia** (Vitamin B12 or folate deficiency), is primarily treated by supplementing the specific deficient nutrient. - Giving EPO would be ineffective unless the underlying nutritional deficit is corrected, as the bone marrow lacks the necessary building blocks for red blood cell production. ***Aplastic anemia*** - Aplastic anemia is a condition of **pancytopenia** caused by bone marrow failure due to the destruction or suppression of hematopoietic stem cells, often immune-mediated. - The primary treatment involves **immunosuppressive therapy** (e.g., antithymocyte globulin) or **hematopoietic stem cell transplantation**, as erythropoietin production is usually adequate, and the bone marrow is simply unable to respond.

Q: Which of the following are correct regarding Blood substitutes ? 1. They are biomimetic. 2. They are extensively used in war injuries. 3. They are made of perfluorocarbon emulsions. 4. They are haemoglobin-based. Select the correct answer using the code given below :

1, 3 and 4. ***1, 3 and 4*** - **Blood substitutes are biomimetic** - they are artificially engineered to mimic the oxygen-carrying capacity of natural red blood cells. - Blood substitutes fall into **two main categories**: perfluorocarbon (PFC) emulsions and hemoglobin-based oxygen carriers (HBOCs). Statement 3 and 4 correctly identify these two major types. - **PFC emulsions** can dissolve large amounts of oxygen and carbon dioxide, transporting gases to tissues through physical dissolution. - **Hemoglobin-based oxygen carriers** use modified hemoglobin (human, bovine, or recombinant) to bind and transport oxygen similar to natural red blood cells. *1, 2 and 3* - While statements 1 and 3 are correct, **statement 2 is incorrect**. - Blood substitutes are **NOT extensively used in war injuries** - most remain experimental or have very limited clinical approval. - Despite theoretical advantages (extended shelf life, no cross-matching needed), practical deployment has been minimal due to safety concerns and regulatory limitations. *2, 3 and 4* - This option incorrectly includes statement 2 about extensive use in war injuries, which is **factually inaccurate**. - Most blood substitutes have failed to gain widespread approval due to adverse effects including vasoconstriction, hypertension, and increased mortality in some trials. - It also incorrectly excludes statement 1 - the **biomimetic nature** is a fundamental defining characteristic of blood substitutes. *1 and 3 only* - While statements 1 and 3 are correct, this option is **incomplete**. - It fails to recognize that blood substitutes include **both perfluorocarbon-based AND hemoglobin-based** types - the two major categories in development. - Statement 4 about hemoglobin-based carriers is equally important and correct.

Q: Complications of heparin therapy in pregnancy include all except :

Teratogenicity. ***Teratogenicity*** - **Heparin** does not cross the placenta due to its large molecular weight, making it a safe anticoagulant choice during pregnancy regarding fetal malformations. - Therefore, it is **not associated with teratogenicity**, unlike some other anticoagulants like warfarin. *Thrombocytopaenia* - **Heparin-induced thrombocytopenia (HIT)** is a known complication, where antibodies against heparin-platelet factor 4 complexes lead to platelet activation and consumption. - While typically Type II HIT is more severe, a mild, transient drop in platelet count (Type I) can also occur. *Osteoporosis* - **Long-term heparin therapy**, particularly unfractionated heparin, is associated with an increased risk of bone demineralization and **osteoporosis** due to its direct effect on osteoblasts and osteoclasts. - This complication is less common with low molecular weight heparin (LMWH) but still a potential concern. *Bleeding* - As an anticoagulant, **heparin's primary mechanism of action** involves inhibiting coagulation factors, which inherently increases the risk of **bleeding**. - The risk of bleeding can range from minor ecchymoses to life-threatening hemorrhages depending on the dose and individual patient factors.

Q: Which parenteral iron preparation does not cause anaphylaxis on intravenous administration?

Iron sucrose. ***Iron sucrose*** - **Iron sucrose** is a newer generation parenteral iron preparation with the **lowest risk of anaphylaxis** among IV iron formulations - This safety profile is primarily due to its **lack of dextran content**, which is responsible for the anaphylactic reactions seen with iron dextran - **Does not require a test dose** before administration, unlike iron dextran - Preferred for **intravenous administration** in patients requiring parenteral iron therapy [1] *Iron fumarate* - **Iron fumarate (ferrous fumarate)** is an **oral iron preparation only**, not a parenteral formulation - Since it is not administered intravenously, this option is **not applicable** to the question about parenteral IV iron preparations - As an oral preparation, it does not carry the risk of anaphylaxis associated with intravenous iron administration *Iron dextran* - **Iron dextran** is an older parenteral iron preparation with the **highest risk of anaphylactic reactions** due to the presence of dextran [2] - **Test dose is mandatory** before full administration due to significant hypersensitivity risk [2] - Can cause both **anaphylactoid reactions** (non-IgE mediated) and **true anaphylaxis** (IgE-mediated) [2] *Iron sorbitol* - **Iron sorbitol** is a parenteral iron preparation primarily used for **intramuscular administration**, not typically given intravenously - Can cause **allergic reactions** and has potential for **cardiovascular side effects** - Less commonly used today due to availability of safer alternatives like iron sucrose and ferric carboxymaltose [3]

Q: Intramuscular injection of iron dextran is given by ‘Z’ technique to:

Reduce the staining. ***Reduce the staining*** - The **Z-track technique** creates a staggered path that prevents the dark iron solution from leaking back into the subcutaneous tissue, which can cause **permanent skin discoloration or staining**. - This method seals the medication deep in the muscle, preventing its reflux along the needle track. *Increase the iron absorption* - The Z-track technique is primarily about preventing **leakage and staining**, not enhancing the absorption rate of the iron. - Iron absorption is largely determined by factors like the patient's iron deficiency status and the form of iron administered, not the injection technique. *Alleviate the pain* - While proper injection technique can minimize discomfort, the Z-track method's primary purpose is not pain reduction but rather **preventing reflux** and associated staining. - Pain during injection is often related to the volume, viscosity, and acidity of the medication, as well as the injection site. *Decrease the incidence of infection* - Standard aseptic techniques, not the Z-track method itself, are crucial for **preventing infection** during intramuscular injections. - The Z-track technique does not inherently reduce the risk of infection beyond what is achieved with good sterile practice.

Q: Which of the following drugs is a direct inhibitor of clotting factor Xa?

Apixaban. ***Apixaban*** - Apixaban is an **oral direct factor Xa inhibitor**, which means it directly binds to and inactivates factor Xa. - This inhibition prevents the conversion of **prothrombin to thrombin**, thereby disrupting the coagulation cascade. *Argatroban* - Argatroban is a **direct thrombin inhibitor** (DTI), meaning it selectively binds to and inhibits thrombin (factor IIa). - It is often used in cases of **heparin-induced thrombocytopenia (HIT)** due to its non-heparin-based mechanism of action. *Fondaparinux* - Fondaparinux is an **indirect factor Xa inhibitor** that binds to antithrombin, thereby enhancing antithrombin's ability to inactivate factor Xa. - It does not directly bind to factor Xa itself, but rather potentiates the action of a natural anticoagulant. *Aspirin* - Aspirin is an **antiplatelet agent** that inhibits cyclooxygenase (COX-1), thereby reducing the production of thromboxane A2. - This mechanism primarily inhibits **platelet aggregation** and adhesion, rather than directly inhibiting a clotting factor in the coagulation cascade.

Q: Which of the following is an oral direct thrombin inhibitor?

Dabigatran. ***Dabigatran*** - **Dabigatran** is the correct answer because it is an **oral direct thrombin inhibitor (DTI)**, meaning it directly inhibits thrombin (factor IIa) to prevent clot formation. - It is one of the **novel oral anticoagulants (NOACs)**, used for conditions like atrial fibrillation and venous thromboembolism. *Lepirudin* - **Lepirudin** is a **direct thrombin inhibitor**, but it is administered **intravenously**, not orally. - It is typically used for **heparin-induced thrombocytopenia (HIT)** when heparin is contraindicated. *Rivaroxaban* - **Rivaroxaban** is an **oral anticoagulant**, but it is a **direct factor Xa inhibitor**, not a direct thrombin inhibitor. - This drug prevents the conversion of prothrombin to thrombin by inhibiting factor Xa. *Warfarin* - **Warfarin** is an **oral anticoagulant**, but it acts as a **vitamin K antagonist (VKA)**, inhibiting the synthesis of coagulation factors II, VII, IX, and X. - It does not directly inhibit thrombin, but rather reduces the production of thrombin precursors.

Q: Which among the following is an iron chelator?

Desferrioxamine. ***Desferrioxamine*** - **Desferrioxamine** is a specific iron chelator used to treat **acute iron poisoning** and chronic iron overload, such as in patients with **thalassemia** requiring frequent transfusions. - It works by binding to free iron in the bloodstream and promoting its **excretion via urine**. *BAL* - **BAL (dimercaprol)** is primarily used as a chelating agent for **heavy metal poisoning**, particularly **arsenic, mercury, and lead** [1], [2]. - While it can chelate some metals, its affinity and primary use are not for iron. *EDTA* - **EDTA (ethylenediaminetetraacetic acid)** is a chelator often used for **lead poisoning** [1], [2] and hypercalcemia. - It has a high affinity for various divalent and trivalent metal ions [2], but it is not the primary or most specific iron chelator. *Penicillamine* - **Penicillamine** is a chelating agent primarily used for the treatment of **copper overload** in **Wilson's disease**. - It is also used in the treatment of severe **rheumatoid arthritis** and **cystinuria**, but not typically for iron chelation.

Q: Which condition is most commonly associated with warfarin-induced skin necrosis?

Protein C deficiency. ***Protein C deficiency***- **Warfarin** inhibits the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) and anticoagulant proteins (Protein C and Protein S) [1, 2].- In individuals with **Protein C deficiency**, warfarin initially reduces Protein C levels faster than the procoagulant factors, leading to a transient **hypercoagulable state** and microthrombi formation, causing skin necrosis [1, 2].*Protein S deficiency*- While **Protein S** is also a vitamin K-dependent anticoagulant and its deficiency can be associated with hypercoagulability, **Protein C deficiency** is the more common and significant predisposing factor for warfarin-induced skin necrosis.- Both Protein C and Protein S deficiencies increase the risk of thrombosis, but the rapid decline of Protein C activity upon warfarin initiation is particularly critical for this specific adverse event.*Factor X deficiency*- **Factor X deficiency** (Stuart-Prower factor) is a bleeding disorder, not a hypercoagulable state.- Individuals with Factor X deficiency would be prone to excessive bleeding, which is the opposite of the thrombotic process seen in warfarin-induced skin necrosis.*Factor VII deficiency*- **Factor VII deficiency** (proconvertin deficiency) is also a bleeding disorder, characterized by impaired extrinsic pathway coagulation.- It would lead to an increased risk of hemorrhage, not the thrombosis observed in warfarin-induced skin necrosis.

Q: Warfarin-induced skin necrosis is more common in patients with

Protein C deficiency. ***Protein C deficiency*** - Warfarin treatment initially depletes protein C, a **natural anticoagulant**, faster than procoagulant factors, leading to a temporary **hypercoagulable state**. - In patients with pre-existing **protein C deficiency**, this imbalance is exaggerated, causing severe microthrombosis and subsequent skin necrosis. *Sickle cell anemia* - While sickle cell anemia is associated with thrombotic events, it does not directly predispose to **warfarin-induced skin necrosis**. - Its pathophysiology involves **hemoglobin S polymerization** and red blood cell sickling, leading to vaso-occlusion and chronic hemolysis. *Antithrombin 3 deficiency* - Antithrombin III deficiency increases the risk of **venous thromboembolism** but is not specifically linked to warfarin-induced skin necrosis. - Warfarin targets vitamin K-dependent clotting factors, and antithrombin III's role is independent of this pathway. *Factor V Leiden mutation* - Factor V Leiden mutation causes **resistance to activated protein C**, increasing the risk of venous thromboembolism. - While it involves protein C, the mechanism of warfarin-induced skin necrosis is due to the **initial pharmacological depletion of protein C concentrations**, not protein C resistance.

Question 1

In which condition erythropoietin will be useful for treatment?

Accepted Answer

Anemia in chronic kidney disease

Answer

Nutritional anemia

Answer

Aplastic anemia

Answer

Anemia in myelodysplastic syndrome

Question 2

Which of the following are correct regarding Blood substitutes ?

1. They are biomimetic.
2. They are extensively used in war injuries.
3. They are made of perfluorocarbon emulsions.
4. They are haemoglobin-based.

Select the correct answer using the code given below :

Accepted Answer

1, 3 and 4

Answer

2, 3 and 4

Answer

1 and 3 only

Answer

1, 2 and 3

Question 3

Complications of heparin therapy in pregnancy include all except :

Accepted Answer

Teratogenicity

Answer

Thrombocytopaenia

Answer

Osteoporosis

Answer

Bleeding

Question 4

Which parenteral iron preparation does not cause anaphylaxis on intravenous administration?

Accepted Answer

Iron sucrose

Answer

Iron fumarate

Answer

Iron dextran

Answer

Iron sorbitol

Question 5

Intramuscular injection of iron dextran is given by ‘Z’ technique to:

Accepted Answer

Reduce the staining

Answer

Increase the iron absorption

Answer

Alleviate the pain

Answer

Decrease the incidence of infection

Question 6

Which of the following drugs is a direct inhibitor of clotting factor Xa?

Accepted Answer

Apixaban

Answer

Argatroban

Answer

Fondaparinux

Answer

Aspirin

Question 7

Which of the following is an oral direct thrombin inhibitor?

Accepted Answer

Dabigatran

Answer

Lepirudin

Answer

Rivaroxaban

Answer

Warfarin

Question 8

Which among the following is an iron chelator?

Accepted Answer

Desferrioxamine

Answer

BAL

Answer

EDTA

Answer

Penicillamine

Question 9

Which condition is most commonly associated with warfarin-induced skin necrosis?

Accepted Answer

Protein C deficiency

Answer

Protein S deficiency

Answer

Factor X deficiency

Answer

Factor VII deficiency

Answer

AT III deficiency

Question 10

Warfarin-induced skin necrosis is more common in patients with

Accepted Answer

Protein C deficiency

Answer

Sickle cell anemia

Answer

Antithrombin 3 deficiency

Answer

Factor V Leiden mutation

Drugs Affecting Blood and Blood Formation — MCQs

Drugs Affecting Blood and Blood Formation — MCQs

On this page

Practice by Chapter

Want unlimited practice?